The Virtues Of Predictability: US Medicare’s Review Of Aduhelm Coverage

Medicare’s decision to initiate a formal review of coverage for the newly approved Alzheimer’s agent is a highly unsettling development in many respects. It is also probably the best possible news for Biogen and Eisai at this point.

In principle, the US Medicare agency’s decision to open up a formal review of coverage policy for

Biogen, Inc./Eisai Co., Ltd.’s Aduhelm (adcanumab-avwa) in Alzheimer’s disease is an unprecedented and unsettling move by the payer...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Medicare

More from Government Payers